Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Antiviral Research|May 8, 2013
Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3aNavaneethan Palanisamy, Axel Danielsson, Chakradhar Kokkula, et al.
Handbook of Experimental Pharmacology|December 3, 2008
Approaches for the development of antiviral compounds: the case of hepatitis C virusRaymond F Schinazi, Steven J Coats, Leda C Bassit, et al.
Biotechnology and Applied Biochemistry|June 21, 2002
Application of a colorimetric chain-termination assay for characterization of reverse transcriptase from 3'-azido-2',3'-deoxythymidine-resistant HIV isolatesXing-Wu Shao, Sandra Hjalmarsson, Johan Lennerstrand, et al.
Microorganisms|October 28, 2023
Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022-2023Jonathan Haars, Navaneethan Palanisamy, Frans Wallin, et al.
Analytical Biochemistry|August 21, 2012
Homogeneous assay for real-time and simultaneous detection of thymidine kinase 1 and deoxycytidine kinase activitiesPer Stålhandske, Liya Wang, Sara Westberg, et al.
International Journal of Molecular Sciences|June 27, 2024
From SARS-CoV-2 to Global Preparedness: A Graphical Interface for Standardised High-Throughput Bioinformatics Analysis in Pandemic Scenarios and Surveillance of Drug ResistanceTomas Cumlin, Ida Karlsson, Jonathan Haars, et al.
Infection Ecology & Epidemiology|October 16, 2018
Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the <i>in silico</i> approachDario Akaberi, Assar Bergfors, Midori Kjellin, et al.
Antiviral Research|April 19, 2021
Targeting the NS2B-NS3 protease of tick-borne encephalitis virus with pan-flaviviral protease inhibitorsDario Akaberi, Amanda Båhlström, Praveen K Chinthakindi, et al.
Hepatology (Baltimore, Md.)|June 23, 2015
Hepatitis C virus drug resistance-associated substitutions: State of the art summaryErik Lontok, Patrick Harrington, Anita Howe, et al.
Infectious Diseases (London, England)|May 26, 2025
Dynamics of SARS-CoV-2 variants and mutations in Central Sweden between 2023 and 2024 and their potential implications on monoclonal antibodies pemivibart and sipavibart as PrEP in the regionJonathan Haars, Frans Wallin, Karin Elfving, et al.
Pageof 4